Cancer-focused immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has been granted a further extension to its option to license the commercial use of Ichor Medical Systems' proprietary TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma.
The extension has been granted at no cost to Scancell, chief executive officer Richard Goodfellow told Proactive Investors.
The two technologies work well together to create T-cells that are highly effective in combating cancer.
“Our technology is validating them and their technology is validating us in a way,” Goodfellow said, which may explain why Ichor was keen for Scancell to continue using the system.
“This extension of two years gives us confidence to embark upon the next round of clinical trials that we’re planning in the United States,” Goodfellow declared.
The company is talking on new people in the US and making a bigger splash across the pond, which is engendering a “much broader knowledge of the company within the biotech field”, Goodfellow said.